<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56110">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02375685</url>
  </required_header>
  <id_info>
    <org_study_id>CL3-78989-019</org_study_id>
    <secondary_id>2013-004973-29</secondary_id>
    <nct_id>NCT02375685</nct_id>
  </id_info>
  <brief_title>Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)</brief_title>
  <acronym>EYEGUARD-X</acronym>
  <official_title>A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate long-term safety of gevokizumab in patient with
      chronic non-infectious uveitis who previously well tolerated the study drug and may benefit
      from longterm treatment with gevokizumab.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoints (adverse events, ...)</measure>
    <time_frame>108 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Chronic Uveitis</condition>
  <arm_group>
    <arm_group_label>gevokizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gevokizumab</intervention_name>
    <arm_group_label>gevokizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  either completed participation to one of the following: CL3-78989-002 open-label
             extension, or X052130/CL3-78989-005 double-masked period or open-label period, or
             X052131/CL3-78989-006 double-masked period or open-label period, or currently
             benefiting from gevokizumab compassionate use after participation in gevokizumab
             uveitis studies

          -  Male or female, age ≥18 (or legal age of majority in the country) at selection.

          -  For subject with reproductive potential, a willingness to use highly effective
             contraceptive measures

        Exclusion Criteria:

          -  Meeting criteria for discontinuation of any of gevokizumab uveitis previous study.

          -  Infectious uveitis and masquerade syndrome

          -  History of severe allergic or anaphylactic reaction to study drug administration
             during previous study or to gevokizumab or any of its excipient.

          -  Currently active infectious disease.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://ghr.nlm.nih.gov/condition/behcet-disease</url>
    <description>Genetics Home Reference</description>
  </link>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/848/behcets-disease/resources/1</url>
    <description>Behcet's Disease</description>
  </link>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/6060/chorioretinitis/resources/1</url>
    <description>Chorioretinitis</description>
  </link>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/8577/panuveitis/resources/1</url>
    <description>Panuveitis</description>
  </link>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/7339/pars-planitis/resources/1</url>
    <description>Pars Planitis</description>
  </link>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/4457/posterior-uveitis/resources/1</url>
    <description>Posterior Uveitis</description>
  </link>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/8192/uveal-diseases/resources/1</url>
    <description>Uveal Diseases</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>U.S. FDA Resources</description>
  </link>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 15, 2015</lastchanged_date>
  <firstreceived_date>February 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uveitis</keyword>
  <keyword>Non-infectious Uveitis</keyword>
  <keyword>Intermediate Uveitis</keyword>
  <keyword>Posterior Uveitis</keyword>
  <keyword>Behçet's disease uveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
